Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue distribution patterns and subsequent downstream effects. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Julia Baguña, Roodselaar, Jay, Sealey, Megan, Ziehn, Marina, Bigaud, Marc, Kneuer, Rainer, Leppert, David, Weckbecker, Gisbert, Cornelissen, Bart, Anthony, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366925/
https://www.ncbi.nlm.nih.gov/pubmed/35967378
http://dx.doi.org/10.3389/fimmu.2022.814064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366925/
https://www.ncbi.nlm.nih.gov/pubmed/35967378
http://dx.doi.org/10.3389/fimmu.2022.814064

Ejemplares similares